Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical studySeptember 28, 2018
OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in AustraliaOctober 29, 2018
- Date of occurrence of the event: Oct 01, 2018
- Company name: OBI Pharma Inc.
- Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
- Reciprocal shareholding ratios: N/A
- Cause of occurrence: OBI received notice from patent attorney’s office that product patent for OBI-822 named ” Compound and Compositions of Carbohydrate Vaccine and Uses Thereof” has been approved by Taiwan Intellectual Property Office (No. 103131876).
- Countermeasures: None
- Any other matters that need to be specified: None